DSM Launches Cellular Therapy Development Services

DSM launched its cellular therapy development services. Cellular therapies use a patient’s own cells to improve healing of an injury or disease. DSM’s expertise lies in the isolation and concentration of autologous cells at the point of care, along with the technologies to deliver these cells independently or in concert with a variety of other biomaterials to enhance therapeutic effect.

DSM offers a complete package of design, development and manufacturing services to create cellular therapy products that are clinically valuable and commercially viable. The first product, launched by DePuy Synthes Mitek Sports Medicine, concentrates platelets from whole blood in only two and a half minutes. The DePuy Synthes Mitek Sports Medicine PEAK™ Platelet Rich Plasma System reportedly yields a higher concentration of undamaged platelets and a more consistent output than existing devices on the market. Further, the device weighs only four pounds, making it easy to store in surgical specialty rooms as well as transport through a doctor’s office or hospital. (Source: DSM)

RELATED ARTICLES



CONTACT BONEZONE

 

CONTACT BONEZONE